GE vs MRK: Which Is the Better Buy?
Side-by-side comparison of GE Aerospace and Merck & Co., Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-09-18.
GE Aerospace · Industrials
$312.90
+3.4% upside to fair value
Med Conviction
Grade C
High Quality
VS
Merck & Co., Inc. · Healthcare
$147.17
-4.1% upside to fair value
Med Conviction
Grade C
QuantHub Verdict
GE has more upside to fair value
(+3.4%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
GE |
MRK |
| Current Price |
$312.90 |
$147.17 |
| Fair Value Estimate |
$323.41 |
$141.07 |
| Upside to Fair Value |
+3.4%
|
-4.1%
|
| Market Cap |
$324.6B |
$363.5B |
| Forward P/E |
—
|
—
|
| EV / EBITDA |
27.4x
|
29.6x
|
| Price / Sales |
6.4x
|
5.5x
|
| Price / FCF |
38.7x
|
22.6x
|
| Revenue Growth YoY |
+21.1%
|
+5.1%
|
| Gross Margin |
35.4%
|
75.4%
|
| Operating Margin |
20.8%
|
16.7%
|
| Return on Equity |
49.0%
|
6.6%
|
| Dividend Yield |
0.53% |
2.31% |
| FCF Yield |
2.58%
|
4.42%
|
| Analyst Consensus |
Buy
|
Buy
|
Investment Thesis
GE Aerospace is a high-quality commercial and military propulsion company whose approximately 50,000 commercial-engine and 30,000 military-engine installed base, long-term service agreements, proprietary repair capabilities and certification barriers support recurring aftermarket economics. The business is executing strongly: revenue grew 21.1% year over year in the most recent quarter, while Q2 …
Merck & Co., Inc. is a global healthcare leader with two core divisions, Pharmaceuticals and Animal Health, spanning oncology, vaccines, acute hospital care, immunology, neuroscience, virology, cardiovascular and diabetes, and it employs roughly 74,000 people under CEO Robert Davis. The business quality is medium: TTM gross margin of 75.4% and TTM operating margin of 16.7% reflect a genuinely hig…
Accumulation Zones
| Metric |
GE |
MRK |
| Zone Low |
$242.56 |
$105.80 |
| Zone High |
$274.90 |
$119.91 |
| In Buy Zone? |
No
|
No
|